ABSTRACT
Although the occurrence of tuberculous meningitis (TBM) in children is relatively rare, but it is associated with higher rates of mortality and severe morbidity. The peak incidence of TBM occurs in younger children who are less than five years of age, and most children present with late-stage disease. Confirmation of diagnosis is often difficult, and other infectious causes such as bacterial, viral and fungal causes must be ruled out. Bacteriological confirmation of diagnosis is ideal but is often difficult because of its paucibacillary nature as well as decreased sensitivity and specificity of diagnostic tests. Early diagnosis and management of the disease, though difficult, is essential to avoid death or neurologic disability. Hence, a high degree of suspicion and a combined battery of tests including clinical, bacteriological and neuroimaging help in diagnosis of TBM. Children diagnosed with TBM should be managed with antituberculosis therapy (ATT) and steroids. There are studies reporting low concentrations of ATT, especially of rifampicin and ethambutol in cerebrospinal fluid (CSF), and very young children are at higher risk of low ATT drug concentrations. Further studies are needed to identify appropriate regimens with adequate dosing of ATT for the management of paediatric TBM to improve treatment outcomes. This review describes the clinical presentation, investigations, management and outcome of TBM in children and also discusses various studies conducted among children with TBM.
Subject(s)
Antitubercular Agents/therapeutic use , Mycobacterium tuberculosis/pathogenicity , Tuberculosis, Meningeal/drug therapy , Antitubercular Agents/cerebrospinal fluid , Child , Child, Preschool , Ethambutol/therapeutic use , Humans , Rifampin/therapeutic use , Steroids/therapeutic use , Treatment Outcome , Tuberculosis, Meningeal/cerebrospinal fluid , Tuberculosis, Meningeal/diagnosis , Tuberculosis, Meningeal/microbiologyABSTRACT
OBJECTIVE: There is considerable uncertainty regarding the optimal use of rifampicin for the treatment of tuberculous (TB) meningitis. A pharmacokinetic modeling and simulation study of rifampicin concentrations in cerebrospinal fluid (CSF) during TB meningitis treatment was performed in this study. METHODS: Parameters for rifampicin pharmacokinetics in CSF were estimated using individual-level rifampicin pharmacokinetic data, and the model was externally validated in three separate patient cohorts. Monte Carlo simulations of rifampicin serum and CSF concentrations were performed. The area under the rifampicin CSF concentration-versus-time curve during 24 h (AUC0-24) relative to the minimum inhibitory concentration (MIC) served as the pharmacodynamic target. RESULTS: Across all simulated patients on the first treatment day, 85% attained the target AUC0-24/MIC ratio of 30 under a weight-based dosing scheme approximating 10 mg/kg. At the rifampicin MIC of 0.5 mg/l, the probability of AUC0-24/MIC target attainment was 26%. With an intensified dosing strategy corresponding to 20 mg/kg, target attainment increased to 99%, including 93% with a MIC of 0.5 mg/l. CONCLUSIONS: Under standard dosing guidelines, few TB meningitis patients would be expected to attain therapeutic rifampicin exposures in CSF when the MIC is ≥0.5 mg/l. Either downward adjustment of the rifampicin MIC breakpoint in the context of TB meningitis, or intensified rifampicin dosing upwards of 20 mg/kg/day, would reflect the likelihood of pharmacodynamic target attainment in CSF.
Subject(s)
Antitubercular Agents/cerebrospinal fluid , Rifampin/cerebrospinal fluid , Tuberculosis, Meningeal/cerebrospinal fluid , Adult , Antitubercular Agents/blood , Antitubercular Agents/pharmacokinetics , Antitubercular Agents/therapeutic use , Humans , Microbial Sensitivity Tests , Monte Carlo Method , Rifampin/blood , Rifampin/pharmacokinetics , Tuberculosis, Meningeal/drug therapyABSTRACT
Pediatric tuberculous meningitis (TBM) is a highly morbid, often fatal disease. Standard treatment includes isoniazid, rifampin, pyrazinamide, and ethambutol. Current rifampin dosing achieves low cerebrospinal fluid (CSF) concentrations, and CSF penetration of ethambutol is poor. In adult trials, higher-dose rifampin and/or a fluoroquinolone reduced mortality and disability. To estimate optimal dosing of rifampin and levofloxacin for children, we compiled plasma and CSF pharmacokinetic (PK) and outcomes data from adult TBM trials plus plasma PK data from children. A population PK/pharmacodynamic (PD) model using adult data defined rifampin target exposures (plasma area under the curve (AUC)0-24 = 92 mg*h/L). Levofloxacin targets and rifampin pediatric drug disposition information were literature-derived. To attain target rifampin exposures, children require daily doses of at least 30 mg/kg orally or 15 mg/kg intravenously (i.v.). From our pediatric population PK model, oral levofloxacin doses needed to attain exposure targets were 19-33 mg/kg. Our results provide data-driven guidance to maximize pediatric TBM treatment while we await definitive trial results.
Subject(s)
Antitubercular Agents/administration & dosage , Drug Dosage Calculations , Levofloxacin/administration & dosage , Models, Biological , Mycobacterium tuberculosis/drug effects , Rifampin/administration & dosage , Tuberculosis, Meningeal/drug therapy , Administration, Intravenous , Administration, Oral , Adolescent , Adult , Age Factors , Antitubercular Agents/blood , Antitubercular Agents/cerebrospinal fluid , Antitubercular Agents/pharmacokinetics , Body Weight , Child , Child, Preschool , Clinical Trials, Phase II as Topic , Computer Simulation , Humans , Infant , Levofloxacin/blood , Levofloxacin/cerebrospinal fluid , Levofloxacin/pharmacokinetics , Randomized Controlled Trials as Topic , Rifampin/blood , Rifampin/cerebrospinal fluid , Rifampin/pharmacokinetics , Tuberculosis, Meningeal/diagnosis , Tuberculosis, Meningeal/microbiologyABSTRACT
para-aminosalicylic acid (PAS; 4-amino-2-hydroxybenzoic acid), an antituberculosis drug in use since the 1950s, has recently been suggested to be an effective agent for treatment of manganese-induced parkinsonian disorders. However, the neuropharmacokinetics of PAS and its metabolite N-acetyl-para-aminosalicylic acid (AcPAS; N-acetyl-4-amino-2-hydroxybenzoic acid) are unknown. This study was designed to investigate the pharmacokinetics of PAS and its distribution in brain to help better design the dosing regimen for clinical trials. Male Sprague-Dawley rats received single femoral artery injections of PAS (200 mg/kg). Plasma, cerebrospinal fluid, and brain tissues were collected, and PAS and AcPAS concentrations were quantified by high-performance liquid chromatography. After administration, the concentrations of PAS declined rapidly in plasma with an elimination t(½) of 34 min; the metabolite AcPAS was detected in plasma and eliminated with a t(½) of 147 min. PAS and AcPAS were detected in brain tissues; AcPAS had a much higher tissue concentration and a longer t(½) than the parent PAS in most tissues examined. Although both were present in blood or tissues as free, unbound molecules, AcPAS appeared to have a higher tissue affinity than PAS. Taken together, our results suggest that a dosing regimen with continuous intravenous infusion of PAS is necessary to achieve therapeutic levels in targeted brain regions. Furthermore, PAS and AcPAS seem to be effective in reducing manganese levels in brain.
Subject(s)
Aminosalicylic Acid/pharmacokinetics , Aminosalicylic Acids/pharmacokinetics , Antitubercular Agents/pharmacokinetics , Brain/metabolism , Chelating Agents/pharmacokinetics , Manganese/metabolism , Aminosalicylic Acid/blood , Aminosalicylic Acid/cerebrospinal fluid , Aminosalicylic Acid/pharmacology , Aminosalicylic Acids/blood , Aminosalicylic Acids/cerebrospinal fluid , Animals , Antitubercular Agents/blood , Antitubercular Agents/cerebrospinal fluid , Antitubercular Agents/pharmacology , Brain/drug effects , Chelating Agents/pharmacology , Chromatography, High Pressure Liquid/methods , Infusions, Intravenous , Male , Parkinsonian Disorders/chemically induced , Parkinsonian Disorders/metabolism , Protein Binding , Rats , Rats, Sprague-DawleyABSTRACT
Tuberculous meningitis (TBM) causes a devastating morbidity and mortality in adults and children. Even in patients presenting at an early stage of disease, deterioration may occur despite apparently adequate therapy. The literature relating to cerebrospinal fluid penetration of antituberculosis agents is reviewed. Amongst the essential antituberculosis agents isoniazid has the best CSF pharmacokinetics reaching peak concentrations (C(max)) only slightly less than in blood. Pyrazinamide also has good CSF penetration and in children receiving dosages of 40 mg/kg the CSF C(max) exceeds the proposed minimal inhibitory concentration of 20 µg/ml. Streptomycin other aminoglycosides and ethambutol have poor CSF penetration and cannot be agents of first choice for TBM treatment. Rifampicin at dosages used in adults seldom reaches CSF concentrations exceeding MIC, but does so more frequently in children when dosages of up to 20 mg/kg are used. The non-essential agents ethionamide, the fluoroquinolones, with the exception of ciprofloxacin, and cycloserine (terizadone) have relatively good CSF penetration and are recommended for TBM treatment. The dosages of the essential agents recommended for the treatment of TBM in children are INH 10 mg/kg (range 6-15 mg/kg bodyweight), rifampicin 15 mg/kg (range 10-20 mg/kg), pyrazinamide 35 mg/kg (range 30-40 mg/kg), ethambutol 20 mg/kg (range 15-25 mg/kg) and streptomycin 15 mg/kg (range 12-18 mg/kg). Amongst second-line agents ofloxacin, levofloxacin and moxifloxacin should be used in dosages of 15-20 mg/kg, ethionamide 20 mg/kg in a single dose, if tolerated, and for cycloserine (terizadone) 15 mg/kg. Antituberculous chemotherapy should be started as soon as the diagnosis of TBM is considered.
Subject(s)
Antitubercular Agents/cerebrospinal fluid , Isoniazid/cerebrospinal fluid , Pyrazinamide/cerebrospinal fluid , Rifampin/cerebrospinal fluid , Tuberculosis, Meningeal/cerebrospinal fluid , Adult , Antitubercular Agents/pharmacokinetics , Child , Dose-Response Relationship, Drug , Female , Humans , Isoniazid/pharmacokinetics , Male , Pyrazinamide/pharmacokinetics , Rifampin/pharmacokinetics , Tuberculosis, Meningeal/drug therapyABSTRACT
Moxifloxacin (MFX) is a useful agent in the treatment of multi-drug-resistant tuberculosis (MDR-TB). At Tuberculosis Centre Beatrixoord, a referral center for tuberculosis in the Netherlands, approximately 36% of the patients have received MFX as treatment. Based on the variability of MFX AUC, the variability of in vitro susceptibility to MFX of M. tuberculosis, and the variability of penetration into sanctuary sites, measuring the concentration of MFX in plasma and cerebrospinal fluid (CSF) could be recommended. Therefore, a rapid and validated liquid chromatography-tandem mass spectrometry (LC-MS-MS) analyzing method with a simple pretreatment procedure was developed for therapeutic drug monitoring of MFX in human plasma and CSF. Because of the potential influence of protein binding on efficacy, we decided to determine both bound and unbound (ultrafiltrate) fraction of MFX. The calibration curves were linear in the therapeutic range of 0.05 to 5.0 mg/L plasma and CSF with CV in the range of -5.4% to 9.3%. MFX ultrafiltrate samples could be determined with the same method setup for analysis of MFX in CSF. The LC-MS-MS method developed in this study is suitable for monitoring MFX in human plasma, plasma ultrafiltrate, and CSF.
Subject(s)
Aza Compounds/blood , Aza Compounds/cerebrospinal fluid , Quinolines/blood , Quinolines/cerebrospinal fluid , Tandem Mass Spectrometry/methods , Antitubercular Agents/blood , Antitubercular Agents/cerebrospinal fluid , Antitubercular Agents/pharmacokinetics , Antitubercular Agents/therapeutic use , Area Under Curve , Aza Compounds/pharmacokinetics , Aza Compounds/therapeutic use , Calibration , Chromatography, High Pressure Liquid/methods , Drug Monitoring/methods , Fluoroquinolones , Humans , Imipramine/analogs & derivatives , Imipramine/analysis , Moxifloxacin , Quinolines/pharmacokinetics , Quinolines/therapeutic use , Reproducibility of Results , Tuberculosis, Meningeal/drug therapy , UltrafiltrationABSTRACT
OBJECTIVE: [corrected] To describe a case of culture-proven multidrug-resistant tuberculous (MDR-TB) meningitis, in which the patient survived long enough for clinicians to adjust antituberculous therapy to second-line therapeutic agents. DESIGN: Case report. SETTING: Tertiary care hospital. PATIENT: Twenty-one-month-old girl with MDR-TB meningitis. INTERVENTIONS: Initial standard treatment failed. Subsequent treatment with second-line therapeutic agents including ciprofloxacin, cycloserine, ethambutol, ethionamide, and rifabutin were given for approximately two years. Concentrations of these drugs were measured in serum and cerebrospinal fluid in the presence and absence of meningeal inflammation. MAIN OUTCOME MEASURES/RESULTS: The patient survived for approximately two years after initiation of second-line anti-TB therapy. During this treatment, she developed a ventriculo-peritoneal shunt tunnel tract infection secondary to MDR-TB. CONCLUSIONS: All TB meningitis isolates for which the source case antibiotic susceptibility pattern is not known should be cultured and susceptibility tested using rapid broth techniques. Measurement and subsequent adjustment of therapeutic drug concentrations may optimize therapy with second-line anti-TB drugs in TB meningitis. Better pediatric formulations and pharmacokinetic data for second-line and anti-TB therapeutic agents are needed.
Subject(s)
Antitubercular Agents/therapeutic use , Drug Resistance, Multiple , Tuberculosis, Meningeal/drug therapy , Antitubercular Agents/blood , Antitubercular Agents/cerebrospinal fluid , Drug Resistance, Microbial , Female , Humans , Infant , Mycobacterium tuberculosis/drug effects , Mycobacterium tuberculosis/isolation & purification , Tuberculosis, Meningeal/microbiologyABSTRACT
A direct in-line pre-column extraction technique in which guanidinium and ammonium sulfate are used, followed by column switching, was employed to analyze serum, plasma and cerebrospinal fluid samples of patients treated for tuberculous meningitis. Resolution of a wide range of polar to non-polar xenobiotics was obtained on a C8 silica column by using a linear gradient from a binary system consisting of solvent A (0.05 M KH2PO4) and solvent B (acetonitrile-isopropanol, 4:1, v/v). Apart from the antituberculosis drugs (isoniazid, pyrazinamide, ethionamide and rifampicin) the patients received up to sixteen different medicines for prevention of complications and the treatment of symptoms. Qualitative resolution of all the drugs was obtained by the chromatographic system. Quantitation of pyrazinamide and ethionamide was achieved with high precision and low inter-sample variation.
Subject(s)
Antitubercular Agents/analysis , Antitubercular Agents/blood , Antitubercular Agents/cerebrospinal fluid , Chromatography, High Pressure Liquid , Drug Monitoring , Ethionamide/analysis , Ethionamide/blood , Ethionamide/cerebrospinal fluid , Humans , Isoniazid/analysis , Isoniazid/blood , Isoniazid/cerebrospinal fluid , Pyrazinamide/analysis , Pyrazinamide/blood , Pyrazinamide/cerebrospinal fluid , Spectrophotometry, Ultraviolet , Tuberculosis, Meningeal/blood , Tuberculosis, Meningeal/cerebrospinal fluid , Tuberculosis, Meningeal/drug therapy , Xenobiotics/blood , Xenobiotics/cerebrospinal fluidABSTRACT
Tuberculous meningitis is a very serious form of tuberculosis. In the absence of randomized controlled trials of alternative treatment regimens, its management depends on employing potent drugs that penetrate well into the cerebrospinal fluid (CSF). The penetration of isoniazid, rifampin, and streptomycin into the CSF of 27 Chinese patients was studied using fluorimetric and microbiologic procedures. Isoniazid rapidly diffused into the CSF, peak concentrations in excess of 3 mg/L, or over 30 times its minimal inhibitory concentration (MIC) against Mycobacterium tuberculosis being attained within 4 hr. In contrast, rifampin and streptomycin penetrated very slowly across the meninges, and CSF levels only slightly in excess of their MICs against M. tuberculosis were achieved. The penetration of the drugs into the CSF correlated poorly with differences in their partitioning between octanol/water and cyclohexane/water but could be predicted using a simple model based on their renal clearance rates and plasma protein binding. It is recommended that patients with tuberculous meningitis should be treated for at least 9 months with a combination of isoniazid, rifampin, and pyrazinamide, which may be supplemented in the first 2 mo with streptomycin.
Subject(s)
Antitubercular Agents/cerebrospinal fluid , Tuberculosis, Meningeal/cerebrospinal fluid , Administration, Oral , Adult , Aged , Antitubercular Agents/administration & dosage , Drug Therapy, Combination , Humans , Isoniazid/administration & dosage , Isoniazid/cerebrospinal fluid , Middle Aged , Models, Biological , Prognosis , Rifampin/administration & dosage , Rifampin/cerebrospinal fluid , Spinal Puncture , Streptomycin/administration & dosage , Streptomycin/cerebrospinal fluid , Time Factors , Tuberculosis, Meningeal/drug therapyABSTRACT
Sixteen patients with oral isoniazid, pyrazinamide, rifampin, and intramuscular streptomycin for tuberculous meningitis were studied. The concentrations of isoniazid, pyrazinamide, rifampin, and streptomycin in cerebrospinal fluid (CSF) obtained 3 hours after administration were 2.40, 34.78, 0.29, and 3.78 micrograms/ml, respectively. The CSF concentrations of isoniazid and pyrazinamide were well above the minimum inhibitory concentration for Mycobacterium tuberculosis. Concentrations of rifampin and streptomycin were above the minimal inhibitory concentration initially but declined below the minimal inhibitory concentration at later times. The CSF penetration of isoniazid, pyrazinamide, rifampin, and streptomycin was about 89%, 91%, 5%, and 20%, respectively. In eight patients who received antituberculous drugs in combination with steroids, the mean CSF and serum concentrations, as well as CSF/serum ratios at various intervals of treatment, were not statistically different (p greater than 0.05) from those of the eight patients who did not receive steroids.
Subject(s)
Antitubercular Agents/cerebrospinal fluid , Steroids/pharmacology , Tuberculosis, Meningeal/drug therapy , Adult , Aged , Antitubercular Agents/blood , Antitubercular Agents/therapeutic use , Female , Humans , Isoniazid/blood , Isoniazid/cerebrospinal fluid , Isoniazid/therapeutic use , Male , Middle Aged , Pyrazinamide/blood , Pyrazinamide/cerebrospinal fluid , Pyrazinamide/therapeutic use , Rifampin/blood , Rifampin/cerebrospinal fluid , Rifampin/therapeutic use , Streptomycin/blood , Streptomycin/cerebrospinal fluid , Streptomycin/therapeutic use , Tuberculosis, Meningeal/blood , Tuberculosis, Meningeal/cerebrospinal fluidABSTRACT
There are no published data defining efficacious drug therapy for obese patients with active tuberculosis. Current dosage recommendations are based on total body weight (TBW); drug toxicity might result in obese patients receiving TBW doses. Peak and trough serum levels were measured for rifampin, streptomycin, ethambutol, and pyrazinamide in an obese patient (166 kg TBW, 87 kg ideal body weight (IBW] with miliary and meningeal tuberculosis. The observed drug levels and the calculated serum half-lives of these drugs were compared with the expected serum levels and serum half-lives in lean patients treated with literature-recommended doses. The observed serum levels in our obese patients were within the expected range for lean patients when dosage was based on IBW rather than on TBW. The observed cerebrospinal fluid penetrations of the drugs studied in our obese patient were similar to those reported in lean patients.